Development of a novel therapy targeting tight-junction protein occludin against hepatitis C

为了预防和治疗丙型肝炎病毒（HCV）感染，我们制备了一种新的抗人闭塞蛋白单克隆抗体。纯化的抗体有15个克隆对人肝癌细胞株Huh7.5.1无毒性。这些抗体在Huh7.5.1单层培养中不能抑制HCV感染。然而，当将荧光标记抗体应用于下腔时，在上腔培养的Huh7.5.1细胞沿细胞边界检测到信号，表明该新型抗体在活细胞中与occludin结合。

To prevent and treat Hepatitis C virus (HCV) infection, we generated a novel monoclonal antibody against human occludin. 15 clones of the purified antibodies showed no toxicity in the human hepatocellular carcinoma cell line Huh7.5.1. These antibodies did not inhibit HCV infection in Huh7.5.1 monolayer culture. However, when the fluorescent labeling antibody was applied to the lower chamber, the signal was detected along cell borders of Huh7.5.1 cells cultured in the upper chamber, suggesting that the novel antibody binds to occludin in living cells.